Efruxifermin Fast Tracked for Nonalcoholic Steatohepatitis
Efruxifermin is a differentiated Fc-FGF21 fusion protein designed to mimic the biological activity of fibroblast growth factor 21.
Metabolic
Analogs, Pen Devices Dominate Ambulatory Insulin Use in US Adults
Uptake of newer insulin products increased from 2016 to 2020 for ambulatory use in U.S. adults with type 2 diabetes.
Should NICE Reconsider Inclisiran Recommendation?
Researchers examined NICE’s conclusions on inclisiran’s clinical outcomes, safety, and cost, which they say warrant more transparent data.
Natriuretic Peptides Linked to Lower Risk for Type 2 Diabetes
Researchers sought to discover whether high natriuretic peptides are associated with a lower risk of type 2 diabetes in people with and without cardiovascular disease.
Finerenone Reduces Cardiac Events in Comorbid T2D, Kidney Disease
Chronic kidney disease increases the risk of cardiovascular events associated with type 2 diabetes. A clinical trial sought to discover if finerenone would help patients with both of these conditions.
Statin Therapy Decisions by Patients and Doctors Compared By Technology
An online technology was developed to assess whether physicians and potential patients who may benefit from statin therapy would come to the same diagnostic conclusion.
Risk for COVID-19-Related Hospitalization Increases After Age 40 in T1DM
Children and younger individuals with type 1 diabetes had better outcomes and milder disease.
Intermittent Fasting Is a Safe Diet Pattern for T2D and Metabolic Syndrome
Intermittent fasting can be safe and effective for glycemic control in patients with type 2 diabetes or metabolic syndrome, according to research results published in Diabetes Research and Clinical Practice.
Glucose-Regulating Drugs Improve COVID-19 Outcomes in Diabetes
Findings include GLP-1R agonists and pioglitazone use, with drop in hospital admissions.
Ezetimibe Plus Statin Therapy Reduces Post-ACS Cardiovascular Event Risk
Researchers evaluated the association between baseline LDL-C and treatment with ezetimibe plus statins in post-acute coronary syndrome.
- Loading...
Loading...
Loading... 
Loading...